Cancer related mortality in multiple sclerosis. A population based cohort study

被引:3
|
作者
Grytten, Nina [1 ,2 ,3 ,12 ]
Myhr, Kjell-Morten [2 ,3 ]
Celius, Elisabeth G. [4 ,5 ]
Benjaminsen, Espen [6 ]
Midgard, Rune [7 ,8 ]
Vatne, Anita [9 ]
Aarseth, Jan H. [10 ]
Mannseth, Janne [10 ,11 ]
Torkildsen, Oivind [2 ,3 ]
机构
[1] Haukeland Hosp, Norwegian Multiple Sclerosis Competence Ctr, Dept Neurol, N-5021 Bergen, Norway
[2] Univ Bergen, Dept Clin Med, Bergen, Norway
[3] Haukeland Hosp, Dept Neurol, Neurosysmed, Bergen, Norway
[4] Oslo Univ Hosp Ulleval, Dept Neurol, Oslo, Norway
[5] Univ Oslo, Inst Clin Med, Oslo, Norway
[6] Nordland Hosp, Dept Neurol, Bodo, Norway
[7] Molde Hosp, Dept Neurol, Molde, Norway
[8] Norwegian Univ Sci & Technol, Trondheim, Norway
[9] Southern Norway Hosp, Dept Rehabil, Flekkefjord, Norway
[10] Haukeland Hosp, Dept Neurol, Norwegian Multiple Sclerosis Registry & Biobank, Bergen, Norway
[11] Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway
[12] Haukeland Hosp, Norwegian Multiple Sclerosis Competence Ctr, Dept Neurol, N-5021 Bergen, Norway
关键词
Multiple sclerosis; Cancer; Mortality; Cohort study; DIAGNOSTIC-CRITERIA; EXCESS MORTALITY; SURVIVAL; DEATH; COMORBIDITY; REGISTRY; DELAYS; RISK;
D O I
10.1016/j.msard.2022.104417
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Cancer is a major cause of death, but how cancer influences mortality risk in Multiple Sclerosis (MS) is unclear. Objectives: Determine all-cause mortality and mortality following a cancer diagnosis among MS patients compared with matched population controls. Methods: Norwegian MS patients born 1930 - 1979 (n= 6950) followed-up 1953 - 2016, were matched with 37 922 controls. We compared incident cancer diagnosis from the Cancer Registry of Norway, date of death from the Cause of Death Registry, education from the National Education Database, by multivariate Cox proportional hazard regression.Results: Hazard ratio (HR) and 95% confidence interval (CI) for all-cause mortality among MS patients was 4.97 (4.64 - 5.33), and 2.61 (2.29 - 2.98) for mortality following a cancer diagnosis. Mortality in MS was highest following urinary- (2.53: 1.55 - 4.14), colorectal- (2.14: 1.47 - 3.11), hematological- (1.76: 1.08 - 2.88), ovarian - 2.30 (1.73-3.06) and breast cancer diagnosis (2.61: 1.85 - 3.68), compared to controls. High education was inversely associated with mortality among MS patients.Conclusions: All-cause mortality was five- fold and mortality following a cancer diagnosis was two- fold increased among MS patients. Mortality following specific cancers raises the possibility of diagnostic neglect.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Incidence of cancer in multiple sclerosis before and after the treatment era- a registry- based cohort study
    Grytten, Nina
    Myhr, Kjell-Morten
    Celius, Elisabeth G.
    Benjaminsen, Espen
    Kampman, Margitta T.
    Midgard, Rune
    Vatne, Anita
    Aarseth, Jan H.
    Riise, Trond
    Torkildsen, Oivind
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 55
  • [32] Colorectal Cancer Survival in Multiple Sclerosis A Matched Cohort Study
    Marrie, Ruth Ann
    Maxwell, Colleen
    Mahar, Alyson
    Ekuma, Okechukwu
    McClintock, Chad
    Seitz, Dallasl
    Groome, Patti
    NEUROLOGY, 2021, 97 (14) : E1447 - E1456
  • [33] Mortality among offspring of women diagnosed with cancer: A population-based cohort study
    Verkooijen, Helena M.
    Ang, Joella X.
    Liu, Jenny
    Czene, Kamila
    Salim, Agus
    Hartman, Mikael
    INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (10) : 2432 - 2438
  • [34] The mortality rate of Parkinson's disease and related comorbidities: a nationwide population-based matched cohort study in Korea
    Yoon, Seo Yeon
    Shin, Jaeyong
    Kim, Yong Wook
    Chang, Jee Suk
    Kim, Hye Won
    AGE AND AGEING, 2021, 50 (04) : 1182 - 1188
  • [35] Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study
    Pontieri, Luigi
    Blinkenberg, Morten
    Bramow, Stephan
    Papp, Viktoria
    Rasmussen, Peter, V
    Kant, Matthias
    Schaefer, Jakob
    Mathiesen, Henrik K.
    Jensen, Michael B.
    Sirakov, Georgi
    Berg, Jonas M.
    Kopp, Tine, I
    Joensen, Hanna
    Sellebjerg, Finn
    Magyari, Melinda
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (02) : 496 - 504
  • [36] Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study
    Wilson, Sarah
    Calocer, Floriane
    Rollot, Fabien
    Fauvernier, Mathieu
    Remontet, Laurent
    Tron, Laure
    Vukusic, Sandra
    Le Page, Emmanuelle
    Debouverie, Marc
    Ciron, Jonathan
    Ruet, Aurelie
    De Seze, Jerome
    Zephir, Helene
    Moreau, Thibault
    Lebrun-Frenay, Christine
    Laplaud, David-Axel
    Clavelou, Pierre
    Labauge, Pierre
    Berger, Eric
    Pelletier, Jean
    Heinzlef, Olivier
    Thouvenot, Eric
    Camdessanche, Jean Philippe
    Leray, Emmanuelle
    Dejardin, Olivier
    Defer, Gilles
    LANCET REGIONAL HEALTH-EUROPE, 2023, 24
  • [37] Sarcoidosis-related mortality and the impact of corticosteroid treatment: A population-based cohort study
    Sikjaer, Melina Gade
    Hilberg, Ole
    Ibsen, Rikke
    Lokke, Anders
    RESPIROLOGY, 2022, 27 (03) : 217 - 225
  • [38] Bone metastasis, skeletal-related events, and mortality in lung cancer patients: A Danish population-based cohort study
    Cetin, Karynsa
    Christiansen, Christian Fynbo
    Jacobsen, Jacob Bonde
    Norgaard, Mette
    Sorensen, Henrik Toft
    LUNG CANCER, 2014, 86 (02) : 247 - 254
  • [39] Predictors of Excess Mortality After Fracture: A Population-Based Cohort Study
    Melton, L. Joseph, III
    Atkinson, Elizabeth J.
    St Sauver, Jennifer L.
    Achenbach, Sara J.
    Therneau, Terry M.
    Rocca, Walter A.
    Amin, Shreyasee
    JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 (07) : 1681 - 1690
  • [40] Interface of Multiple Sclerosis, Depression, Vascular Disease, and Mortality A Population-Based Matched Cohort Study
    Palladino, Raffaele
    Chataway, Jeremy
    Majeed, Azeem
    Marrie, Ruth Ann
    NEUROLOGY, 2021, 97 (13) : E1322 - E1333